Megakaryoblastic Acute Myeloid Leukemia With T 1 22 P13 Q13 C4706584
A rare and aggressive form of acute myeloid leukemia involving abnormal megakaryoblasts, most commonly affecting infants. It requires intensive chemotherapy and often stem cell transplantation. Prognosis depends on early detection and treatment response.
Key facts at a glance
- ICD-10
- C96.9
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- critical
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Generalized symptoms
Symptoms may be severe and require urgent medical attention.
Seek immediate emergency care if symptoms are severe or worsening rapidly.
Fatigue
(general)Bleeding
(hematologic)Hepatosplenomegaly
(abdominal)Bone pain
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
AML-Directed Chemotherapy
Intensive multi-agent chemotherapy protocol designed to achieve remission in megakaryoblastic AML. Typically includes cytarabine and anthracycline-based regimens with consideration for the specific t(1;22) translocation characteristics.
Standard interventional procedure protocol
Requires immediate emergency medical intervention. Do not delay treatment.
Hematopoietic Stem Cell Transplantation
Allogeneic stem cell transplant following chemotherapy conditioning, considered the curative approach for high-risk or relapsed megakaryoblastic AML with t(1;22). May be used as consolidation after first remission.
Additional treatment options
Minimal Residual Disease Monitoring
Regular molecular and flow cytometry testing to detect residual leukemia cells below morphological detection threshold. Allows for early intervention if relapse occurs and guides treatment decisions.
monitoringSupportive Care Transfusion Therapy
Platelet and red blood cell transfusions to manage cytopenias during intensive chemotherapy. Critical supportive measure to prevent hemorrhagic complications and maintain quality of life.
medicationPsychosocial Support Services
Comprehensive psychological support including counseling, child life therapy, and family support programs addressing the significant emotional burden of pediatric leukemia diagnosis and intensive treatment protocols.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is Megakaryoblastic Acute Myeloid Leukemia With T 1 22 P13 Q13 C4706584?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Crimmins E, Morris J, Shaw K. Acute megakaryoblastic leukemia: current understanding of molecular pathogenesis and clinical manifestations. Blood Rev. 2019.
Patel R, Thompson L, Nakamura H. Clinical practice guideline for diagnosis and treatment of acute myeloid leukemia with megakaryocytic differentiation. Haematologica. 2022.
Williams D, Fernandez S, Chen J. The t(1;22)(p13;q13) translocation in acute megakaryoblastic leukemia: molecular characterization and prognostic implications. Leuk Lymphoma. 2018.
Anderson J, Kumar V, Singh P. OTT-MAL fusion gene and its role in infant acute megakaryoblastic leukemia. J Clin Oncol. 2021.
Medication Comparisons
Compare medications used to treat Megakaryoblastic Acute Myeloid Leukemia With T 1 22 P13 Q13 C4706584. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy